An Interventional Study of Letermovir for Primary Prophylaxis of Cytomegalovirus Infection in Moderate Risk (R+) Abdominal Solid Organ Transplant Recipients
An Interventional Study of Letermovir for Primary Prophylaxis of Cytomegalovirus Infection in Moderate Risk (R+) Abdominal Solid Organ Transplant Recipients
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV.
Participants will take letermovir for 84 days.
This study is being done to see if letermovir prevents CMV reactivation in seropositive participants with a kidney or liver transplant.
Inclusion Criteria:
Exclusion Criteria:
surgeryresearch@surgery.wisc.edu608-576-0788
mjorgenson@uwhealth.org